Financials Positive

2026-08-26 18:30

- Honasa Consumer Limited sent communication regarding tax deduction at source on the final dividend of ₹3/- per equity share for FY 2025-26. Approval is subject to the AGM on September 28, 2026. The record date is August 28, 2026, and the last date for TDS document submission is September 10, 2026.

Business Update Negative

2026-08-25 21:04

- Honasa Consumer Limited called off the proposed acquisition of 58% equity stake in Fluence Pharma Private Limited on August 25, 2026. - The acquisition was terminated due to non-fulfilment of closing conditions specified under the Share Purchase Agreement. - The company remains committed to its Nutraceutical strategy.

Business Update Positive

2026-08-19 18:29

- Q1 FY27 results show 32% growth, EBITDA of approximately ₹110Cr, and PAT of approximately ₹90Cr, with 30.5% volume growth. - Management reported a significant YoY improvement in EBITDA profile, with 300-350 basis points expansion from mix/operating leverage and 50 bps from seasonality/one-time opex in Q1. - The company is committed to expanding EBITDA margin by 100-150 basis points annually to reach 15% in five years, expecting 150-200 bps improvement this year while prioritizing growth investments. - Focus categories grew 35%+, e-commerce 20%+ growth, and GT/Modern Trade saw 40%+ secondary sales growth. - Mamaearth accelerated to high teens growth in Q1 FY27. The Derma Co became the second ₹1000Cr brand, and newly acquired BTM Ventures reached ₹150Cr ARR. - Honasa launched a new fragrance brand FIKN and is developing new Mamaearth products like moisturizers, sunscreens, and new face wash/shampoo partitions targeting significant ARR contributions in the coming years.

Ownership Neutral

2026-08-18 11:11

- ICICI Prudential Life Insurance Company Limited sold 892,850 shares of Honasa Consumer Limited on August 14, 2026. - This reduced their shareholding from 7.61% (as of Jan 31, 2025) to 5.53%.

Business Update Neutral

2026-08-13 22:34

- Audio recording of the Earnings Conference Call held on August 13, 2026, for the unaudited Q1 FY27 financial results (quarter ended June 30, 2026) is available on the company website.

Governance Positive

2026-08-13 15:59

- 10th Annual General Meeting (AGM) will be held on Monday, September 28, 2026. - Record Date for the final dividend of ₹3/- per equity share for FY 2025-26 is Friday, August 28, 2026, subject to AGM approval. - Cut-off Date for e-voting is Monday, September 21, 2026.

Financials Positive

2026-08-13 15:47

- Q1 FY27 Consolidated Revenue ₹755.95 Cr vs ₹595.25 Cr (▲27.0% YoY) - EBITDA ₹110.25 Cr vs ₹45.81 Cr (▲140.7% YoY) - PAT ₹90.45 Cr vs ₹41.33 Cr (▲118.9% YoY) - EBITDA Margin 14.58% vs 7.69% (▲689bps) - Major litigation with RSM General Trading LLC resolved in favor of the company; RSM is liable to pay Honasa approximately ₹25.54 Cr. - Board recommended a final dividend of ₹3/- per equity share for FY26. - Approved acquisition of 58% equity stake in Fluence Pharma Private Limited. - Approved incorporation of a new wholly-owned subsidiary, Honasa Health Private Limited, for nutraceuticals business.

Financials Positive

2026-08-13 15:39

- Q1 FY27 Consolidated Revenue ₹785 Cr vs ₹595.6 Cr (▲31.8% YoY) - EBITDA ₹110 Cr vs ₹55 Cr (▲100% YoY) - PAT ₹90 Cr - EBITDA Margin 14.1% vs 9.2% (▲490bps)

Financials Positive

2026-08-13 15:36

- Q1 FY27 Consolidated Revenue ₹785Cr vs ₹595Cr (▲31.8% YoY) - EBITDA ₹110Cr vs ₹45.8Cr (▲140.2% YoY) - PAT ₹90Cr - EBITDA Margin 14.1% vs 7.7% (▲636bps) - Company witnessed highest ever quarterly revenue and profit.

Financials Positive

2026-08-13 15:33

- Q1 FY27 Consolidated Revenue ₹755.95Cr vs ₹595.25Cr (▲27% YoY) - EBITDA ₹132.76Cr vs ₹69.70Cr (▲90% YoY) - PAT ₹90.25Cr vs ₹41.33Cr (▲118% YoY) - EBITDA Margin 17.6% vs 11.7% (▲590bps) - Legal suit with RSM General Trading LLC resolved in favor of Honasa, with RSM liable to pay approximately ₹255.36Cr in damages. - Board recommended a final dividend of ₹3/- per equity share. - Approved acquisition of 58% equity stake in Fluence Pharma Private Limited. - Incorporated 'Honasa Health Private Limited' as a wholly-owned subsidiary for nutraceuticals business.

Business Update Neutral

2026-08-11 18:31

- Investor Meeting Schedule - Meeting Date: Tuesday, August 18, 2026 - Meeting Time: 6:30 am - 2:30 pm (IST) - Event: 'Ambit-Daiwa India Access' by Ambit Capital Pvt Ltd. - Location: Singapore

Business Update Neutral

2026-08-08 09:35

- Honasa Consumer Limited provided an update on ongoing litigation with RSM General Trading LLC in Dubai Courts. - The Dubai Cassation Court, on July 29, 2026, dismissed appeals and upheld a previous judgment awarding AED 1,707,407.06 (INR 4,43,12,369/-) to RSM as compensation. - RSM's appeal seeking AED 45,000,000 in damages was rejected by the Cassation Court. - An Indian Arbitral Tribunal, on May 14, 2025 (amended June 26, 2026), passed an Arbitral Award in favor of Honasa, enjoining RSM from further Dubai proceedings and requiring RSM to pay damages to Honasa. - The Company expects no financial impact due to the reliefs granted under the Indian Arbitral Award, noting that the governing law is Indian.

Governance Positive

2026-08-06 14:36

- Honasa Consumer Limited announced the elevation of Mr. Nilesh Kotalwar, SVP - Online Revenue, to Chief Marketing Officer (CMO). - The appointment is effective from August 06, 2026. - He will lead the company's integrated marketing function across its portfolio of brands.

Business Update Neutral

2026-07-31 18:31

- Concall Schedule - Concall Date: Thursday, August 13, 2026 - Concall Time: 5:30 pm (IST)

Governance Neutral

2026-07-29 17:36

- Board meeting scheduled for August 13, 2026, to approve unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. - The trading window remains closed for designated persons until 48 hours after results submission.

Financials Positive

2026-07-09 09:02

- Honasa Consumer Limited expects to deliver strong YoY growth around thirties (mid-twenties on reported basis) in Q1 FY27. - Mamaearth brand projected high-teens YoY growth; younger brands projected early forties YoY growth. - Anticipates sustaining a double-digit operating margin profile in Q1 FY27.

Business Update Positive

2026-07-07 17:31

- Honasa Health Private Limited incorporated as a wholly owned subsidiary of Honasa Consumer Limited. - Date of incorporation: July 7, 2026.

Business Update Positive

2026-06-26 23:02

- Honasa Consumer Limited received a favorable rectification order in arbitration against RSMM General Trading LLC on June 26, 2026. - The final amended award directs RSM to pay Honasa a total of AED 9,918,514 (approx. INR 25.53 Cr). - The order also includes an upward revision of loss of profits and protection against Dubai proceedings.

Routine Neutral

2026-06-26 13:19

- Honasa Consumer Limited announced the closure of its trading window from July 1, 2026. - The window will remain closed until 48 hours after the submission of unaudited financial results for the quarter ended June 30, 2026, as per SEBI PIT Regulations.

Business Update Positive

2026-06-23 18:24

- Honasa Consumer Limited acquired a 58% majority stake in Fluence Pharma. - This marks Honasa's strategic entry into the high-growth nutraceuticals category. - Fluence Pharma reported approximately ₹40 Crore revenue and 20%+ EBITDA margin in FY26. - Honasa will establish Honasa Health Private Limited as a dedicated subsidiary to scale a B2C nutrition portfolio.

Business Update Positive

2026-06-23 18:19

- Honasa Consumer acquired a 58% equity stake in Fluence Pharma Private Limited for an enterprise value of ~₹135 Cr, marking its entry into the nutraceuticals segment. - Fluence Pharma specializes in condition-specific OTC supplements (Hair Fact, Skin Fact, Pro Fact). - Honasa also incorporated 'Honasa Health Private Limited' as a wholly-owned subsidiary for B2C nutraceuticals operations. - Fluence Pharma reported ~INR 40 Cr revenue and 20%+ EBITDA margin in FY26 (provisional).

Ownership Neutral

2026-06-15 12:28

- Honasa Consumer Limited allotted 6,54,422 fully paid-up equity shares of face value ₹10/- each to employees on June 15, 2026.- These shares were issued under various ESOP plans upon exercise of vested stock options, leading to an increase in the company's paid-up share capital.

Business Update Positive

2026-05-28 17:50

Management guided for Honasa Consumer Limited to grow at a high-teens CAGR over the next 5 years, aiming to improve EBITDA by 500 basis points on the bottom line over the same period. Mamaearth is expected to deliver a double-digit CAGR over the next 5 years, increasing its distribution to 0.5 million outlets. Focus categories and younger brands, including The Derma Co. (INR750 Cr+ ARR) and Reginald (INR100 Cr+ ARR, doubled revenue YoY), are expected to continue driving strong growth. The company declared a dividend of INR3 per equity share for FY26 and has implemented price hikes in Q1 to manage inflation.

Governance Neutral

2026-05-22 19:43

Honasa Consumer Limited has submitted its revised Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information to the stock exchanges. This revision was approved by the Board of Directors at its meeting held on May 21, 2026, and is in compliance with Regulation 8(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. The updated code will also be hosted on the company's website.

Business Update Neutral

2026-05-21 20:13

Honasa Consumer Limited announced on May 21, 2026, the availability of the audio recording of its Earnings Conference Call. The call discussed the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The recording can be accessed on the company's website.

Financials Positive

2026-05-21 17:07

CRITICAL RED FLAG DETECTED

Standalone Revenue for Q4 FY26 was ₹6,076.48Mn vs ₹5,225.72Mn (▲16.28% YoY), EBITDA ₹681.66Mn vs ₹239.14Mn (▲184.99% YoY), and PAT ₹644.73Mn vs ₹246.14Mn (▲161.94% YoY). EBITDA Margin expanded to 11.22% from 4.58% (▲664bps). The Board also recommended a maiden final dividend of ₹3/- per equity share for FY26.

Financials Positive

2026-05-21 17:04

CRITICAL RED FLAG DETECTED

Standalone Operating Revenue ₹607.65Cr vs ₹522.57Cr (▲16.28% YoY), EBITDA ₹85.93Cr vs ₹44.24Cr (▲94.21% YoY), PAT ₹64.47Cr vs ₹24.61Cr (▲161.93% YoY). EBITDA Margin 14.14% vs 8.47% (▲567bps). The Board also recommended a maiden final dividend of ₹3/- per equity share for FY2025-26.

Governance Positive

2026-05-21 17:01

The Board of Directors of Honasa Consumer Limited, at its meeting on May 21, 2026, approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. A maiden final dividend of ₹3/- per equity share was recommended for FY 2025-26. The Board also approved the re-appointment of Mr. Subramaniam Somasundaram as an Independent Director and the appointment of BDO India Services Private Limited as Internal Auditors. Additionally, three Senior Management Personnel were appointed. A complex legal dispute was resolved favorably, with an award passed in the Company's favour.

Financials Positive

2026-05-21 16:56

CRITICAL RED FLAG DETECTED

Standalone Revenue ₹6,076.48Mn vs ₹5,225.72Mn (▲16.28% YoY), EBITDA ₹681.66Mn vs ₹239.14Mn (▲185.09% YoY), PAT ₹644.73Mn vs ₹246.14Mn (▲161.93% YoY). EBITDA Margin 11.22% vs 4.58% (▲664bps). The Board also recommended a final dividend of ₹3/- per equity share.

Financials Positive

2026-05-21 16:51

Consolidated Revenue ₹657.08Cr vs ₹533.56Cr (▲23.16% YoY), EBITDA ₹95.97Cr vs ₹47.76Cr (▲100.95% YoY), PAT ₹69.44Cr vs ₹24.98Cr (▲177.90% YoY). EBITDA Margin 14.60% vs 8.95% (▲565bps). The Board also recommended a final dividend of ₹3 per equity share and resolved a significant legal dispute in the company's favor.

544014

Honasa Consumer Ltd

Price Chart

Filing History

Unlock Full History